Abstract / Summary
To evaluate the safety and effectiveness of laser therapy on urethral hemangioma. We retrospectively analyzed the clinical records of consecutive patients who underwent transurethral laser hemostasis for urethral hemangioma between July 2018 and August 2025. After applying the exclusion criteria, 32 patients were included in the final analysis. All patients were completed successfully and without patient transfer to the intensive care unit. The median operative time was 40.0 min [P 25 , P 75 : (30.0, 63.8) minutes], and the procedures were associated with minimal blood loss, evidenced by a median volume of 2.0 mL [P 25 , P 75 : (0.0, 5.0) mL]. The median durations of indwelling catheterization and postoperative hospitalization were 5.0 days [P 25 , P 75 : (2.3, 6.0) days] and 7.0 days [P 25 , P 75 : (5.0, 8.0) days], respectively. No intraoperative complications occurred in this series. During the postoperative period, only one patient (3.1%) developed urethral hemorrhage, which resolved with conservative management. No other complications were recorded, including urinary incontinence, ejaculatory pain, urethral stricture, or retrograde ejaculation. After a median follow-up of 4.0 months [P25, P75: (2.0, 43.5) months; range: (0.0, 86.0) months], all patients remained free of recurrence, urethral stricture, urinary incontinence, and hematuria. The transurethral laser hemostasis with high complete hemangioma resection, less intraoperative blood loss, extremely low perioperative complication rate, and short-term relapse rate may be safe and effective in treating urethral hemangioma, and it is worthy of promotion for use in clinical work.